Biotech | October 28, 2021
MSD and MPP sign licensing agreement to make molnupiravir affordable
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
It answers the most basic questions from a patient’s perspective
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Subscribe To Our Newsletter & Stay Updated
